MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 125682 | Name: EB-PSMA-617
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.

Chemical Structure

EB-PSMA-617
EB-PSMA-617
CAS#2250333-97-0

Theoretical Analysis

MedKoo Cat#: 125682

Name: EB-PSMA-617

CAS#: 2250333-97-0

Chemical Formula: C88H112N16O28S3

Exact Mass: 1936.6994

Molecular Weight: 1938.13

Elemental Analysis: C, 54.54; H, 5.83; N, 11.56; O, 23.11; S, 4.96

Price and Availability

Size Price Availability Quantity
1mg USD 1,250.00 Ready to ship
2mg USD 2,050.00 Ready to ship
5mg USD 3,650.00 Ready to ship
10mg USD 6,450.00 Ready to ship
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
EB-PSMA-617; EB-PSMA 617; EB PSMA-617; EB PSMA 617; EB-PSMA617;
IUPAC/Chemical Name
(((1S)-5-((2R)-2-(4-((2-((1-(3-(((S)-6-((4'-((E)-(8-amino-1-hydroxy-5,7-disulfonaphthalen-2-yl)diazenyl)-3,3'-dimethyl-[1,1'-biphenyl]-4-yl)amino)-6-oxo-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)hexyl)amino)-3-oxopropyl)-2,5-dioxopyrrolidin-3-yl)thio)acetamido)methyl)cyclohexane-1-carboxamido)-3-(naphthalen-2-yl)propanamido)-1-carboxypentyl)carbamoyl)-L-glutamic acid
InChi Key
FJXZIJARXATZAM-FDCGHPRFSA-N
InChi Code
InChI=1S/C88H112N16O28S3/c1-51-39-58(59-20-23-62(52(2)40-59)98-99-63-24-21-60-69(134(127,128)129)44-70(135(130,131)132)80(89)79(60)81(63)117)19-22-61(51)94-84(120)64(93-72(106)46-100-31-33-101(47-76(111)112)35-37-103(49-78(115)116)38-36-102(34-32-100)48-77(113)114)11-5-7-28-90-71(105)27-30-104-74(108)43-68(85(104)121)133-50-73(107)92-45-53-13-17-56(18-14-53)82(118)95-67(42-54-15-16-55-9-3-4-10-57(55)41-54)83(119)91-29-8-6-12-65(86(122)123)96-88(126)97-66(87(124)125)25-26-75(109)110/h3-4,9-10,15-16,19-24,39-41,44,53,56,64-68,117H,5-8,11-14,17-18,25-38,42-43,45-50,89H2,1-2H3,(H,90,105)(H,91,119)(H,92,107)(H,93,106)(H,94,120)(H,95,118)(H,109,110)(H,111,112)(H,113,114)(H,115,116)(H,122,123)(H,124,125)(H2,96,97,126)(H,127,128,129)(H,130,131,132)/t53-,56-,64-,65-,66-,67+,68?/m0/s1
SMILES Code
S(=O)(=O)(O)C=1C2=C(C(O)=C(N=NC3=C(C)C=C(C=C3)C4=CC(C)=C(NC([C@@H](NC(CN5CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC5)=O)CCCCNC(CCN6C(=O)C(SCC(NC[C@@H]7CC[C@@H](C(N[C@H](CC8=CC9=C(C=C8)C=CC=C9)C(NCCCC[C@H](NC(N[C@@H](CCC(O)=O)C(O)=O)=O)C(O)=O)=O)=O)CC7)=O)CC6=O)=O)=O)C=C4)C=C2)C(N)=C(S(=O)(=O)O)C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,938.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, Li F, Jacobson O, Niu G, Zhu Z, Chen X. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):148-158. doi: 10.1007/s00259-018-4096-y. Epub 2018 Aug 8. PMID: 30090965; PMCID: PMC6250576. 2: Lu Q, Long Y, Gai Y, Liu Q, Jiang D, Lan X. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy. Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2342-2352. doi: 10.1007/s00259-023-06155-x. Epub 2023 Mar 6. PMID: 36877233. 3: Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, Zhu Z, Chen X. 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020 Dec;61(12):1772-1778. doi: 10.2967/jnumed.120.242263. Epub 2020 May 1. PMID: 32358086; PMCID: PMC9364902. 4: Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, Kiesewetter DO, Jacobson O, Chen X. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018 Sep 19;29(9):3213-3221. doi: 10.1021/acs.bioconjchem.8b00556. Epub 2018 Aug 22. PMID: 30105912. 5: Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, Zhang J, Zhang X, Guo Z, Chen X. Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25. PMID: 37097443. 6: Ghodsirad MA, Pirayesh E, Akbarian R, Javanmard B, Kaghazchi F, Tavakoli M, Fattahi K. Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging. Urol J. 2020 Jun 23;17(4):374-378. doi: 10.22037/uj.v0i0.5451. PMID: 32281092.

View History

UC-1728

UC-1728

New Featured